NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-18-509 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support research to deepen our knowledge of the use of synthetic psychoactive drugs, their mechanisms of action, their health effects, and development of prevention strategies and strategies to treat patients in emergency departments and long range treatment.
Funding Opportunity PA-18-471 from the NIH Guide for Grants and Contracts. This initiative seeks to optimize innovation, insight and cutting edge conceptual and technological breakthroughs by catalyzing research that emanates from the identified innovative questions in symptom and genomic nursing science. These innovative questions are reflective of broad domains from which more specific novel hypotheses or problems to be solved can be derived.
Funding Opportunity PA-18-472 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to encourage interdisciplinary research to decrease symptom burden and enhance health-related quality of life (HRQL) in persons with chronic illness through a) increasing knowledge of the biological mechanisms of symptoms and b) promoting innovative, cost-effective, targeted interventions to prevent, manage or ameliorate these symptoms.
Funding Opportunity PAR-18-513 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to develop and implement Phase I to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and other age-related dementias using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure.
Notice NOT-NS-18-030 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-18-376 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage research that seeks to build the science of self-management for health in chronic conditions. This FOA focuses on self-management as a mainstream science to reduce the burden of chronic illnesses/conditions.
Funding Opportunity PA-18-384 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage research that seeks to build the science of self-management for health in chronic conditions. This FOA focuses on self-management as a mainstream science to reduce the burden of chronic illnesses/conditions.
Funding Opportunity PA-18-474 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage research that seeks to build the science of self-management for health in chronic conditions. This FOA focuses on self-management as a mainstream science to reduce the burden of chronic illnesses/conditions.
Funding Opportunity PA-18-499 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) seeks to stimulate research focused on identification of the key barriers to effective end-of-life and palliative care (EOLPC) health literacy in diverse settings and populations, and to create novel strategies, interventions, and models of care to improve EOLPC health literacy, with the goal of improving outcomes for individuals with serious, advanced illness and their families and caregivers.
Funding Opportunity PA-18-498 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) seeks to stimulate research focused on identification of the key barriers to effective end-of-life and palliative care (EOLPC) health literacy in diverse settings and populations, and to create novel strategies, interventions, and models of care to improve EOLPC health literacy, with the goal of improving outcomes for individuals with serious, advanced illness and their families and caregivers.
Funding Opportunity PA-18-500 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to encourage applications that seek to conduct studies of the visual system. Eligible applications may be either: Those that involve human subjects, but are not NIH-defined clinical trials (see NOT-OD-15-015); or Those that are NIH-defined clinical trials and are designed to address either: 1) mechanisms underlying human vision in health and disease; or 2) interventions that entail procedures with minimal risk to subjects. More information about eligibility can be found in Part 2 Section III.3. A mechanistic trial is defined as "A study designed to understand a biological or behavioral process, the pathophysiology of a disease, or the mechanism of action of an intervention. "Minimal risk" means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. NIH-defined clinical trial applications that are neither mechanistic nor minimal risk are not eligible for this FOA. Large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials are not appropriate for this FOA. Applicants are strongly advised to consult with NEI program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity.
Funding Opportunity PAR-18-433 from the NIH Guide for Grants and Contracts. This FOA will support exploratory/developmental research projects of interest to the NIBIB (https://www.nibib.nih.gov/research-funding). These studies are expected to lead to breakthroughs in development of innovative techniques, agents, methodologies, models, or their applications. These studies may involve considerable risk that should be balanced by the potential high impact on human-health and related research. Applicants are expected to propose novel biomedical research approaches for which there is no preliminary data to demonstrate the feasibility of the proposed project. A project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven.
Funding Opportunity PAR-18-497 from the NIH Guide for Grants and Contracts. This FOA is aimed at molecular, cellular, genetic, epigenetic, and systems biology approaches to advance basic and clinical research on the causes and consequences of sleep deficiency and circadian clock dysfunction in Alzheimer's disease, and the roles of sleep and the circadian clock as modifiers of the progression of neurodegeneration.
Funding Opportunity RFA-AG-18-028 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications proposing to conduct research involving pragmatic clinical trials into improving the effectiveness of treatment strategies for comorbid conditions that occur frequently in combination with Alzheimers disease and related dementia (ADRD).
Funding Opportunity PAR-18-434 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to conduct research to advance the understanding and application of synthetic biology for human health. It will support 1) the development of innovative tools and technologies in synthetic biology and 2) their application in biomedical research and human health. An integrative research plan based on collaborations of synthetic biologists with computational scientists, cell biologists, engineers, and/or physician scientists is strongly recommended. Early Stage Investigators in Synthetic Biology are especially encouraged to apply.
Funding Opportunity RFA-AG-18-029 from the NIH Guide for Grants and Contracts. This funding opportunity announcement invites comprehensive, cross-disciplinary studies aimed at building predictive molecular models of cognitive resilience based on high-dimensional molecular data collected in individuals who remain free of dementia despite being at high risk for Alzheimers disease.
Funding Opportunity RFA-AG-18-027 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites innovative research focused on understanding the role of exosome biogenesis and secretion in modulating and propagation of early pathogenesis in sporadic and late-onset Alzheimers disease (AD). Specifically, this FOA encourages collaborative approaches designed to identify and characterize the regulation of molecular machines that are responsible for exosome biogenesis and the secretion of exosomal cargo molecules in AD.
Funding Opportunity RFA-AG-18-026 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits innovative and collaborative research focused on understanding the structure and function of proteins or protein complexes regulated by different AD genetic variants that have been identified to be associated with the sporadic and late onset Alzheimers disease (AD). Specifically, NIA is interested in identifying and developing more effective and integrated platforms to screen protein functions, protein-protein interaction, protein complexes and their regulation by AD genetic variants prior to any in-depth mechanistic studies. The program encourages collaborative research projects that will translate initial GWAS discovery into functional and phenotypical insights and ultimately lead to understand the complex biology of AD.
Funding Opportunity PA-18-503 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages exploratory or developmental research grant applications to develop new tools, methods, and models focused on palliative care in geriatric populations. This FOA covers studies in a variety of settings including hospitals (and specific sites within hospitals including specialty medical or surgical wards, intensive care units, and emergency departments), post-acute care settings, outpatient clinics and doctors offices, patients homes and other residential settings, assisted living facilities, nursing homes, hospices, and other healthcare or community settings. This FOA encourages both prospective studies and analyses of existing datasets, health and medical records, claims data, or other sources. Leveraging ongoing cohorts, intervention studies, networks, data and specimen repositories, and other existing research resources and infrastructure are encouraged. Study designs may include observational approaches, quasi-experimental designs, and limited interventional studies where feasible for this R21 mechanism.
Funding Opportunity PA-18-502 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages research grant applications focused on palliative care in geriatric populations. This FOA covers studies in a variety of settings including hospitals (and specific sites within hospitals including specialty medical or surgical wards, intensive care units, and emergency departments), post-acute care settings, outpatient clinics and doctors offices, patients homes and other residential settings, assisted living facilities, nursing homes, hospices, and other healthcare or community settings. This FOA encourages both prospective studies and analyses of existing datasets, health and medical records, claims data, or other sources. Leveraging ongoing cohorts, intervention studies, networks, data and specimen repositories, and other existing research resources and infrastructure are encouraged. Study designs may include observational approaches, quasi-experimental designs, and interventional studies.